The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review

    September 2025 in “ Dermatology and Therapy ”
    H.A. Dayem, Anwar Al Hammadi, Ashraf Reda … Muna Al Murrawi
    Studysummary This study reviewed the burden of alopecia areata in the UAE, noting limited regional data on patient demographics and treatments but highlighting the approval and promising results of the Janus kinase inhibitor baricitinib for managing this condition.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 26

    1. Efficacy and Safety of the Oral Janus Kinase 3/Tyrosine Kinase Inhibitor Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb/III and Long-Term Phase III Clinical Studies in Alopecia Areata British Journal of Dermatology · 2024
    2. Long-Term Efficacy of Baricitinib in Alopecia Areata: 3-Year Results from BRAVE-AA1 and BRAVE-AA2 Journal of the American Academy of Dermatology · 2024
    3. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    4. Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries Dermatology and therapy · 2024
    5. Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2 Journal of the European Academy of Dermatology and Venereology · 2024
    6. European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2024
    7. Physician and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries Dermatology and therapy · 2023
    8. Effectiveness and Safety of Baricitinib in Patients With Severe Alopecia Areata: A 36-Week Multicenter Real-World Experience Journal of Dermatological Treatment · 2023
    9. Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials British Journal of Dermatology · 2023
    10. Ritlecitinib: First Approval Drugs · 2023
    11. Economic Burden of Alopecia Areata: A Study of Direct and Indirect Cost in Japan Using Real-World Data Journal of dermatology · 2023
    12. Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East Dermatology and therapy · 2023
    13. Review on Alopecia Areata in the Middle East and Africa: Landscape and Unmet Needs Dermatology and therapy · 2023
    14. Prevalence of Autoimmune and Inflammatory Diseases and Mental Health Conditions Among an Alopecia Areata Cohort from a US Administrative Claims Database Journal of Dermatology · 2023
    15. Baricitinib for the Treatment of Alopecia Areata Drugs · 2023
    16. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    17. The Burden of Alopecia Areata: A Scoping Review Focusing on Quality of Life, Mental Health, and Work Productivity Journal of the European Academy of Dermatology and Venereology · 2023
    18. Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials British journal of dermatology/British journal of dermatology, Supplement · 2022
    19. An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata Frontiers in immunology · 2022
    20. Epidemiological Trends in Alopecia Areata at the Global, Regional, and National Levels Frontiers in immunology · 2022
    21. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    22. The Associated Burden of Mental Health Conditions in Alopecia Areata: A Population-Based Study in UK Primary Care British Journal of Dermatology · 2022
    23. Response of Alopecia Areata of the Beard to Oral Tofacitinib Journal of the American Academy of Dermatology · 2019
    24. Alopecia Areata of the Beard: A Review of the Literature American Journal of Clinical Dermatology · 2017
    25. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    26. Randomized Comparison of Topical Betamethasone Valerate Foam, Intralesional Triamcinolone Acetonide, and Tacrolimus Ointment in Management of Localized Alopecia Areata International journal of trichology · 2011